Replies to post #55934 on RespireRx Pharmaceuticals Inc (fka RSPI)

[LTListener]

That was for recent deal with Jazz. SAN711 is a similar selective gabakine that Respire mentioned or compared to in publications.

Acadia licensed it..

Saniona will receive up to US $610 million, including a US $28 million upfront payment and up to US $582 million in development, regulatory, and commercial milestone payments, along with tiered royalties from mid single digits to low double digits on global net sales of SAN711